Bharati Vidyapeeth Deemed University
Pune, India

Bharati Vidyapeeth Deemed University College of Engineering, Pune is an engineering and technology oriented institute of higher education established in 1983. This engineering college is the constituent college of Bharati Vidyapeeth. Wikipedia.

Time filter
Source Type

Ramanojam S.,Bharati Vidyapeeth Deemed University
Journal of Craniofacial Surgery | Year: 2017

ABSTRACT: Idiopathic sialolithiasis is one of the most common affliction of the salivary glands with the submandibular gland most frequently involved. The article discusses the occurrence and incidence of this condition with a review of different diagnostic and treatment modalities. In light of several advances to diagnose and treat sialolithiasis, a simple sialolithotomy for idiopathic submandibular gland sialolithiasis may prove to be a preferred treatment for selected patients as it remains a cost-effective and simple out-patient department procedure with minimal/no complications and a highly satisfactory outcome. For stones slightly proximal in the Wharton duct, a “dual” approach of milking the gland to bring the stone more distally followed by a sialolithotomy with a scalpel proves to be a quick and effective procedure. © 2017 by Mutaz B. Habal, MD.

Dhaneshwar S.S.,Bharati Vidyapeeth Deemed University | Vadnerkar G.,Bharati Vidyapeeth Deemed University
Current Topics in Medicinal Chemistry | Year: 2011

Earlier colon was considered as a black-box, acting as a site for production and temporary storage of excreta and responsible for absorption of electrolytes and water. But, with the discovery of sulfasalazine as colon-specific pro-drug, the promising and challenging issue of treating local pathologies was presented with colon as an organ of significance for target-specific delivery of drugs. The need and desirable attributes of colon-specific drug delivery systems have been well recognized, extensively explored and documented in the literature. The success of a colon-specific prodrug depends on its rational design and understanding the demands of the organ to be targeted and the delivery system to be developed. The present review mainly focuses on anatomy/physiology of colon, colonic microbiota, enzymatic set up of colon, pathophysiology of local diseases of colon, factors, obstacles and rationale for designing colon specific drug delivery system, various targets, potential drug candidates and novel colon-targeting carriers along with varied linkages that could be explored, merits and demerits of this design and recent trends in this field. Brief review of methodologies for characterization and in vitro/in vivo release studies is presented. The available animal models with quantifying parameters for evaluating colon-targeting potential and effectiveness of the colon-specific prodrugs for inflammatory bowel disease is also included in this review. © 2011 Bentham Science Publishers.

Patil-Gadhe A.,Bharati Vidyapeeth Deemed University | Pokharkar V.,Bharati Vidyapeeth Deemed University
European Journal of Pharmaceutics and Biopharmaceutics | Year: 2014

The purpose of the study was to formulate montelukast-loaded nanostructured lipid carrier (MNLC) to improve its systemic bioavailability, avoid hepatic metabolism and reduce hepatic cellular toxicity due to metabolites. MNLC was prepared using melt-emulsification-homogenization method. Preformulation study was carried out to evaluate drug-excipient compatibility. MNLCs were prepared using spatially different solid and liquid lipid triglycerides. CAE (DL-Pyrrolidonecarboxylic acid salt of L-cocyl arginine ethyl ester), a cationic, biodegradable, biocompatible surfactant was used to stabilize the system. MNLCs were characterized by FTIR, XRPD and DSC to evaluate physicochemical properties. MNLCs having a particle size of 181.4 ± 6.5 nm with encapsulation efficiency of 96.13 ± 0.98% were prepared. FTIR findings demonstrated no interaction between the drug and excipients of the formulation which could lead to asymmetric vibrations. DSC and XRPD study confirmed stable amorphous form of the montelukast in lipid matrix. In vitro release study revealed sustained release over a period of 24 h. In vivo single dose oral pharmacokinetic study demonstrated 143-fold improvement in bioavailability as compared to montelukast-aqueous solution. Thus, the result of this study implies that developed MNLC formulation be suitable to sustain the drug release with improvement in the bioavailability. © 2014 Elsevier B.V.

Bodhankar S.L.,Bharati Vidyapeeth Deemed University
Asian Pacific Journal of Tropical Disease | Year: 2012

Objective: Arthritis is a severe debilitating chronic disease. The objective of the present investigation was to evaluate the clinical outcome and cost effectiveness of anti-rheumatoid arthritis regimen for the treatment of arthritis. Methods: The patients were classified into three treatment cohorts on the basis of the treatment regimens prescribed by the physicians. These were group I consisting of patients treated with monotherapy of non-steroidal anti- inflammatory drugs alone, group II consisting of patients treated with disease modifying anti rheumatoid drugs + non-steroidal anti- inflammatory drugs and group III consisting of patients treated with disease modifying anti rheumatoid drugs along with oral Corticosteroids. The patient reported outcome was measured using European questionnaire 5 dimension 3 levels (EQ-5D-3L) and European questionnaire visual analogue scale (EQ-VAS) before and after the treatment regimen. Clinical outcome was measured using Clinical disease activity index (CDAI). The details of costs were recorded by interviewing the patients. Results: The patient reported outcome measured by EQ-5D-3L and EQ-VAS was significantly improved in patients belonging to group III when compared to group II (P < 0.05) and I (P < 0.001) respectively. The outcomes of CDAI scores demonstrate that the mean change in CDAI levels was 7.04, 12.01 and 16.98 in group I, II and III respectively. Total cost incurred per patient was found to be equal to Rs. 1120 ($19.6) in group I, Rs. 1685 ($29.49) in group II and Rs. 2465 ($43.14) in group III. The ACER was determined as 159.09 in group I, 140.299 in group II and 145.17 in group III. Conclusion: Amelioration of arthritis in clinics can be effectively measured by validated instruments (EQ-5D-3L, EQ-VAS, CDAI) and DMARDs along with NSAIDs are the most cost effective therapy for treatment of arthritis. © 2012 Asian Pacific Tropical Medicine Press.

Dhaneshwar S.S.,Bharati Vidyapeeth Deemed University
World Journal of Gastroenterology | Year: 2014

Despite the advent of biological products, such as antitumor necrosis factor-α monoclonal antibodies (infliximab and adalimumab), for treatment of moderate to severe cases of inflammatory bowel disease (IBD), most patients depend upon aminosalicylates as the conventional treatment option. In recent years, the increased knowledge of complex pathophysiological processes underlying IBD has resulted in development of a number of newer pharmaceutical agents like low-molecular- weight heparin, omega-3 fatty acids, probiotics and innovative formulations such as high-dose, oncedaily multi-matrix mesalamine, which are designed to minimize the inflammatory process through inhibition of different targets. Optimization of delivery of existing drugs to the colon using the prodrug approach is another attractive alternative that has been utilized and commercialized for 5-aminosalicylic acid (ASA) in the form of sulfasalazine, balsalazide, olsalazine and ipsalazine, but rarely for its positional isomer 4-ASA - a wellestablished antitubercular drug that is twice as potent as 5-ASA against IBD, and more specifically, ulcerative colitis. The present review focuses on the complete profile of 4-ASA and its advantages over 5-ASA and colon-targeting prodrugs reported so far for the management of IBD. The review also emphasizes the need for reappraisal of this promising but unexplored entity as a potential treatment option for IBD. © 2014 Baishideng Publishing Group Co., Limited. All rights reserved.

Patil-Gadhe A.,Bharati Vidyapeeth Deemed University | Pokharkar V.,Bharati Vidyapeeth Deemed University
Pulmonary Pharmacology and Therapeutics | Year: 2014

Quality by Design (QbD) is a systematic approach to develop drug products which includes evaluation of formulation parameters to achieve defined final product quality. In the present study principles of QbD were extended to the preparation, in-vitro and in-vivo performance of rifapentine-loaded proliposomes for pulmonary inhalation where final product needs to comply with specific properties. The rifapentine-loaded proliposomes for the treatment of tuberculosis were prepared in single step by spray drying method and independent variables were optimized using factorial design approach. Contour plots and multiple regression analysis were used to study the effect of selected independent variables on dependent variables. The effect of presence of drug: hydrogenated soya phosphatidylcholine (HSPC) and type of charged lipid in the formulation at three levels were studied on mass median diameter (MMD), liposomal vesicle size, % encapsulation efficiency (% EE), mass median aerodynamic diameter (MMAD) and fine particle fraction (FPF) as critical quality attributes. Optimized formulation (R-LDPI-7) with drug: HSPC ratio of 1:2 and stearyl amine as charged lipid were found to give respirable proliposomes with MMAD of 1.56±0.16μm and FPF of 92.5±1.5%. Sustained drug release with Higuchi diffusion kinetics was achieved from liposomally encapsulated rifapentine. Pulmonary pharmacokinetics of optimized batch R-LDPI-7 revealed longer retention of drug in lungs with 7 fold increase in both, the mean residence time and t1/2 as compared to R-DPI-0. The study results demonstrated the application of QbD principles and design of experiment (DOE) approach to develop drug encapsulated proliposomes for inhalation by spray drying in single step. © 2013 Elsevier Ltd.

Venkatpurwar V.,Bharati Vidyapeeth Deemed University | Pokharkar V.,Bharati Vidyapeeth Deemed University
Materials Letters | Year: 2011

The present contribution deals with one pot method for synthesis of silver nanoparticles through green route using sulfated polysaccharide isolated from marine red algae (Porphyra vietnamensis). The obtained silver nanoparticles showed surface plasmon resonance centered at 404 nm with average particle size measured to be 13 ± 3 nm. FTIR spectra revealed the involvement of sulfate moiety of polysaccharide for reduction of silver nitrate. The capping of anionic polysaccharide on the surface of nanoparticles was confirmed by zeta potential measurement (-35.05 mV) and is responsible for the electrostatic stability. The silver nanoparticles were highly stable at wide range of pH (2-10) and electrolyte concentration (up to 10 -2 M of NaCl). The dose dependent effect of synthesized silver nanoparticles revealed strong antibacterial activity against gram negative bacteria as compared to gram positive bacteria. © 2011 Elsevier B.V. All rights reserved.

Dhobale M.,Bharati Vidyapeeth Deemed University
International Journal of Developmental Neuroscience | Year: 2014

Proper placental development is essential during pregnancy since it forms the interface between the maternal-foetal circulations and is critical for foetal nutrition and oxygenation. Neurotrophins such as nerve growth factor (NGF), brain derived neurotrophin (BDNF), neurotrophin-3 (NT-3) and neurotrophin-4/5 (NT-4/5) are naturally occurring molecules that regulate development of the placenta and brain. BDNF and NGF also involved in the regulation of angiogenesis. Recent studies suggest that the levels of BDNF and NGF are regulated by docosahexaenoic acid (DHA) which is an important omega-3 fatty acid and is a structural component of the plasma membrane. Oxidative stress during pregnancy may lower the levels of DHA and affecting the fluidity of the membranes leading to the changes in the levels and expression of BDNF and NGF. Therefore altered levels and expression of NGF and BDNF may lead to abnormal foetal growth and brain development that may increase the risk for cardiovascular disease, metabolic syndromes and neurodevelopmental disorders in children born preterm. This review discuss about the neurotrophins and their role in the feto-placental unit during critical period of pregnancy. © 2014 ISDN.

Dhaneshwar S.S.,Bharati Vidyapeeth Deemed University
Inflammation & allergy drug targets | Year: 2014

Disease modifying antirheumatic drugs (DMARDs) is a category of drugs which is used as medication in various arthritic conditions to arrest the progression of disease along with relief from pain. About 83% of population worldwide uses DMARDs. Withdrawal of COX-2 inhibitors because of cardiovascular side effects and short-term action associated with glucocorticoids provided a motivation for development of newer DMARDs. Currently non- biological DMARDs like methotrexate, sulfasalazine, hydroxychloroquine and azathioprine serve the purpose of relieving pain and inhibiting the progression of disease. Biological DMARDs like toclizumab, adalimumab, infliximab, golimumab and abatacept have shown more efficacy and lesser side effects as compared to non- biological DMARDs but their access to patient is less because of higher cost. DMARDs act by different mechanisms against inflammation like inhibition of tumor necrosis factor, suppression of IL-1 and TNF-α, induction of apoptosis of inflammatory cells, by increasing chemotactic factors, inhibition of purine synthesis, pyrimidine metabolism or purine embolism. DMARDs have important applications in diseases like rheumatoid arthritis, Crohn's disease, juvenile idiopathic arthritis, psoriatic arthritis and myasthenia gravis. Present review mainly focuses on DMARDs and their clinical applications giving an overview of their mechanism of action, pharmacokinetic properties, advantages over conventional therapies, shortcomings and recent trends.

Pokharkar V.B.,Bharati Vidyapeeth Deemed University
Pharmaceutical development and technology | Year: 2013

Bicalutamide (BCT) is an antiandrogenic compound belonging to Biopharmaceutics Classification System (BCS) class II drug. Thus it has limited aqueous solubility and hence limited oral bioavailability. The purpose of the present investigation was to obtain stable nanocrystals of BCT with improved kinetic solubility, dissolution and pharmacokinetic profiling. BCT nanocrystals were prepared by antisolvent precipitation method using Soluplus, a novel amphiphilic polymer. Nanocrystals were characterized for particle size, powder X-ray diffraction analysis (PXRD), in vitro dissolution, in vivo pharmacokinetic profile and stability. The obtained nanocrystals had particle size of 168 nm and were spherical in shape. The nanocrystals exhibited fivefold increase in kinetic solubility as compared to pure drug and 85% dissolution in 60 min. PXRD studies established the retention of crystalline polymorphic form II. The in vivo pharmacokinetic study demonstrated that the Cmax and AUC of nanosized BCT were about 3.5 times higher as compared to pure drug. Nanosizing of BCT significantly improved the pharmacokinetic profile of the drug administered to rats. Prepared nanocrystals were found to be stable over the entire stability period. Thus the use of amphiphilic polymer like Soluplus singularly helped in efficient size reduction and stabilization of the drug.

Loading Bharati Vidyapeeth Deemed University collaborators
Loading Bharati Vidyapeeth Deemed University collaborators